GO:0031284 positive regulation of guanylate cyclase activity: Signaling Pathway, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0031284 describes any process that activates or increases the frequency, rate or extent of guanylate cyclase activity, the enzymes that synthesize cyclic GMP (cGMP).
• Guanylate cyclases exist as soluble (sGC) and particulate/membrane-bound (pGC) forms; positive regulation can occur through allosteric modulators, phosphorylation, or protein-protein interactions.
• cGMP produced by guanylate cyclases acts as a second messenger regulating gene expression, smooth muscle relaxation, and neuronal signaling.
• Dysregulation of guanylate cyclase activity is linked to cardiovascular disease, tumor progression, and metabolic disorders.
• CRISPR knockout, point-mutation, knock-in, and overexpression models are essential to dissect causal roles of guanylate cyclase regulators in disease.
• EDITGENE provides end-to-end CRISPR cell model generation and library screening to study positive regulation of guanylate cyclase activity in any cell type.
Description
Positive regulation of guanylate cyclase activity (GO:0031284) is a biological process that encompasses any molecular event leading to increased activity of guanylate cyclases, the enzymes responsible for converting GTP to cyclic GMP (cGMP). This process is central to signal transduction pathways that control vascular tone, neuronal plasticity, and immune cell function. Researchers study this term to understand how extracellular cues, such as hormones or nitric oxide, modulate cGMP levels and downstream physiological responses. The importance of this GO term extends to disease contexts: aberrant guanylate cyclase regulation contributes to hypertension, heart failure, and cancer progression. Recent discoveries of small molecule positive allosteric modulators of guanylyl cyclase A receptor highlight the therapeutic potential of targeting this process. Furthermore, plant guanylate cyclases with catalytic center motifs have been characterized, underscoring the evolutionary conservation of this regulatory mechanism. Understanding GO:0031284 requires integrating biochemical, genetic, and pharmacological approaches to map the activators, effectors, and feedback loops that control cGMP synthesis.
positive regulation of guanylate cyclase activity At A Glance
| GO ID | GO:0031284 |
|---|---|
| GO term | positive regulation of guanylate cyclase activity |
| Ontology | biological_process |
| Synonym | activation of guanylate cyclase activity; stimulation of guanylate cyclase activity; up regulation of guanylate cyclase activity; up-regulation of guanylate cyclase activity; upregulation of guanylate cyclase activity |
| Major function | Increases the rate of cGMP synthesis by guanylate cyclases, amplifying downstream cGMP signaling |
| Related enzymes | Soluble guanylate cyclase (sGC), particulate guanylate cyclase (pGC), guanylyl cyclase A receptor (GC-A) |
| Key second messenger | Cyclic GMP (cGMP) |
| Regulatory inputs | Nitric oxide, natriuretic peptides, phosphorylation, allosteric modulators |
| Disease relevance | Cardiovascular disease, cancer, metabolic disorders |
What Is GO:0031284?
GO:0031284, positive regulation of guanylate cyclase activity, is defined as any process that activates or increases the frequency, rate or extent of guanylate cyclase activity. In other words, it includes all molecular events that enhance the ability of guanylate cyclase enzymes to catalyze the conversion of GTP into cyclic GMP, whether through direct allosteric activation, post-translational modification, or increased enzyme availability.
Why Is positive regulation of guanylate cyclase activity Important in Cell Biology?
Positive regulation of guanylate cyclase activity is a critical control point in cGMP signaling, which governs fundamental processes such as vasodilation, neurotransmission, and immune regulation. Because cGMP is a ubiquitous second messenger, even modest changes in guanylate cyclase activity can have profound physiological consequences. This GO term is therefore essential for understanding how cells adapt to hormonal and mechanical stimuli, and how disruptions in this pathway lead to disease.
• Controls vascular smooth muscle relaxation and blood pressure homeostasis.
• Regulates neuronal excitability and synaptic plasticity through cGMP-dependent pathways.
• Modulates immune cell tumoricidal function, with implications for cancer immunotherapy.
• Involved in metabolic regulation, including hepatocyte responses to insulin and glucagon.
• Target of positive allosteric modulators with therapeutic potential for heart failure.
• Conserved in plants, where guanylate cyclase catalytic motifs are found in protein kinases.
• Dysregulation linked to aggression and hyperactivity in neurobehavioral models.
• Key node in gene expression regulation by cGMP, affecting transcription factors and ion channels.
• Provides a druggable target for cardiovascular and oncological drug discovery.
• Essential for interpreting CRISPR screens aimed at identifying signaling regulators.
What Happens During positive regulation of guanylate cyclase activity?
Activation by Ligands and Allosteric Modulators
In simple terms: Certain molecules bind to guanylate cyclases and turn them on, like a key in a lock.
Positive regulation often begins with the binding of specific ligands or allosteric modulators to guanylate cyclase enzymes. For example, small molecule positive allosteric modulators of guanylyl cyclase A receptor enhance cGMP production in response to natriuretic peptides. In hepatocytes, insulin and glucagon modulate guanylate cyclase activity, demonstrating hormonal control. These activation events increase the catalytic efficiency of the enzyme, leading to elevated cGMP levels.
Post-translational Modifications and Protein Interactions
In simple terms: Chemical tags or partner proteins can change the enzyme's shape and boost its activity.
Phosphorylation and other post-translational modifications can positively regulate guanylate cyclase activity. For instance, protein kinases embedding guanylate cyclase catalytic center motifs in tomato are regulated by phosphorylation. Additionally, protein-protein interactions, such as those involving CARD11 in T cells, can indirectly influence cGMP signaling pathways. These modifications often serve as integration points for multiple signaling cascades.
cGMP Synthesis and Downstream Signaling
In simple terms: Once activated, the enzyme makes cGMP, which then relays the signal inside the cell.
Activated guanylate cyclases convert GTP to cGMP, which acts as a second messenger. cGMP then regulates gene expression by modulating transcription factors, ion channels, and kinases. In endothelial cells, cGMP mediates relaxation in response to compounds like α-pinene and its metabolites. This downstream signaling amplifies the initial positive regulation event into broad cellular responses.
Feedback and Crosstalk with Other Pathways
In simple terms: The cell has brakes and cross-talk that fine-tune how much cGMP is made.
Positive regulation of guanylate cyclase activity is balanced by negative feedback mechanisms, including phosphodiesterases that degrade cGMP. Crosstalk with other signaling pathways, such as the cAMP pathway, can modulate guanylate cyclase activity, as seen in hepatocytes where insulin and glucagon reciprocally regulate the enzyme. In neurobehavioral contexts, pentosidine accumulation due to Akr1a deficiency alters aggression and hyperactivity, potentially through cGMP-linked pathways.
Key Genes Involved in GO:0031284 positive regulation of guanylate cyclase activity
The following genes and proteins are central to the positive regulation of guanylate cyclase activity, based on published literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| GUCY1A1 | Alpha subunit of soluble guanylate cyclase; binds nitric oxide | Target for cardiovascular drugs; knockout models show hypertension |
| GUCY1B1 | Beta subunit of soluble guanylate cyclase; heme-binding | Mutations linked to impaired cGMP signaling |
| NPR1 (GC-A) | Receptor guanylate cyclase for natriuretic peptides | Positive allosteric modulators discovered; heart failure target |
| NPR2 (GC-B) | Receptor guanylate cyclase for C-type natriuretic peptide | Skeletal growth and neuronal development |
| CARD11 | Scaffold protein in lymphocytes; modulates cGMP-dependent pathways | Regulates CD8+ T cell tumoricidal function |
| AKR1A | Aldehyde reductase; deficiency leads to pentosidine accumulation | Linked to aggression and hyperactivity via cGMP |
| MEF2 | Transcription factor; switches to AP-1 program in border zone | Conserved NPPB+ border zone gene program |
| AP-1 | Transcription factor complex; drives gene expression changes | Switches from MEF2 in cardiac border zone |
| PRKG1 | cGMP-dependent protein kinase I; downstream effector | Mediates smooth muscle relaxation |
| PRKG2 | cGMP-dependent protein kinase II; intestinal and bone function | Regulates ion transport and bone growth |
| PDE5A | Phosphodiesterase 5A; degrades cGMP | Negative regulator; target of sildenafil |
| NOS3 | Endothelial nitric oxide synthase; produces NO | Activates soluble guanylate cyclase |
| NOS1 | Neuronal nitric oxide synthase; produces NO | Regulates neurotransmission |
| NPPB | Natriuretic peptide B; ligand for GC-A | Biomarker in heart failure; border zone marker |
| NPPA | Natriuretic peptide A; ligand for GC-A | Regulates blood pressure and volume |
| GUCY2C | Intestinal guanylate cyclase; receptor for STa toxin | Target in colorectal cancer and diarrhea |
| GUCY2D | Retinal guanylate cyclase; phototransduction | Mutations cause Leber congenital amaurosis |
| GUCY2F | Retinal guanylate cyclase; sperm function | Role in fertilization and vision |
How Is positive regulation of guanylate cyclase activity Regulated?
Positive regulation of guanylate cyclase activity is itself regulated at multiple levels. Hormones such as insulin and glucagon can stimulate or inhibit the enzyme in hepatocytes. Nitric oxide produced by NOS enzymes directly activates soluble guanylate cyclase by binding to its heme group. Phosphorylation by protein kinases can enhance or reduce activity depending on the site. Additionally, cGMP levels are kept in check by phosphodiesterases, which provide negative feedback. In immune cells, CARD11 signaling can influence cGMP-dependent pathways, linking antigen receptor signaling to guanylate cyclase regulation.
positive regulation of guanylate cyclase activity and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| NPR1 (GC-A) | Heart failure, hypertension | Knockout mouse; knock-in of human mutation |
| CARD11 | Lymphoma, immunodeficiency | Conditional knockout in T cells |
| AKR1A | Neurobehavioral aggression, hyperactivity | Akr1a knockout mouse |
| GUCY2C | Colorectal cancer, secretory diarrhea | Intestinal epithelial knockout; overexpression |
| GUCY2D | Leber congenital amaurosis | Retinal organoids; point mutation knock-in |
Cardiovascular Disease
Impaired positive regulation of guanylate cyclase activity contributes to hypertension, heart failure, and atherosclerosis. Small molecule positive allosteric modulators of guanylyl cyclase A receptor have been discovered as potential therapeutics for heart failure. Endothelial-dependent relaxation mediated by cGMP is disrupted in vascular disease, as shown with α-pinene metabolites. Natriuretic peptides and their receptor GC-A are key regulators of blood pressure and volume.
Cancer and Immune Regulation
Guanylate cyclase activity influences tumor progression and immune responses. CARD11 signaling regulates CD8+ T cell tumoricidal function, implicating cGMP pathways in cancer immunotherapy. GUCY2C, an intestinal guanylate cyclase, is a target in colorectal cancer. Modulation of cGMP levels can affect cell proliferation and apoptosis.
Neurobehavioral and Metabolic Disorders
Dysregulation of guanylate cyclase activity is linked to neurobehavioral abnormalities. Pentosidine accumulation induced by Akr1a deficiency drives aggression and hyperactivity, potentially through cGMP-dependent mechanisms. In metabolic contexts, insulin and glucagon regulation of hepatocyte guanylate cyclase activity is altered in diabetes. cGMP signaling also modulates neuronal plasticity and may be involved in neurodegenerative conditions.
From positive regulation of guanylate cyclase activity-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of GUCY1A1 reduce cGMP synthesis? | CRISPR knockout in endothelial cells |
| Does a point mutation in NPR1 alter allosteric modulation? | Point mutation knock-in in HEK293 cells |
| Can overexpression of CARD11 enhance cGMP signaling? | Overexpression in Jurkat T cells |
| What is the effect of Akr1a deficiency on aggression? | Akr1a knockout mouse |
| How does NPPB border zone switch affect guanylate cyclase? | MEF2/AP-1 knockout in cardiac cells |
| Does GUCY2C activation affect tumor growth? | Knockout and overexpression in colorectal cancer cells |
How to Study the positive regulation of guanylate cyclase activity Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Radioenzymatic assay | Conversion of GTP to cGMP | Direct measurement of guanylate cyclase activity |
| CRISPR knockout screen | Gene essentiality for cGMP production | Identify positive regulators |
| FRET biosensor imaging | Real-time cGMP dynamics | Live-cell signaling studies |
| RNA-seq | Transcriptional changes | Downstream gene expression |
| Phosphoproteomics | Phosphorylation sites on guanylate cyclases | Post-translational regulation |
| Western blot | Protein expression and phosphorylation | Validate knockout/overexpression |
| ELISA | cGMP levels in cells or tissues | Quantify pathway activation |
| Patch-clamp electrophysiology | Ion channel activity modulated by cGMP | Neuronal and smooth muscle studies |
Biochemical Assays for Guanylate Cyclase Activity
Direct measurement of guanylate cyclase activity is performed using radioenzymatic assays that quantify the conversion of GTP to cGMP. These assays are essential to confirm positive regulation in response to ligands or modulators. They can be coupled with pharmacological inhibitors to dissect specific enzyme isoforms.
CRISPR Screening and Functional Genomics
Genome-wide CRISPR knockout screens can identify genes whose loss alters guanylate cyclase activity or cGMP levels. Such screens have been used to uncover regulators of immune cell function, including CARD11. Libraries targeting kinases and signaling proteins are particularly useful for mapping positive regulators.
Imaging and Reporter Systems
Genetically encoded cGMP biosensors, such as cGMP-dependent FRET reporters, allow real-time imaging of guanylate cyclase activity in living cells. These tools have been applied to study endothelial relaxation and neuronal signaling. They provide spatial and temporal resolution of positive regulation events.
Transcriptomics and Proteomics
RNA-seq and proteomics can reveal downstream gene expression changes following manipulation of guanylate cyclase activity. For example, the NPPB+ border zone switch from MEF2 to AP-1 was identified using transcriptomics. Phosphoproteomics can identify post-translational modifications that positively regulate guanylate cyclases.
How CRISPR Can Be Used to Study GO:0031284 positive regulation of guanylate cyclase activity
Knockout
CRISPR knockout of guanylate cyclase genes or their regulators is used to determine loss-of-function phenotypes. For example, knockout of GUCY1A1 reduces cGMP synthesis and impairs vasodilation. Knockout of CARD11 in T cells abrogates tumoricidal function, linking to cGMP pathways. These models are essential for target validation.
Point Mutation
Point mutation knock-in allows precise modeling of disease-associated variants. For instance, mutations in NPR1 that alter allosteric modulation can be introduced to study heart failure mechanisms. Point mutations in GUCY2D linked to retinal degeneration can be modeled in photoreceptor cells. This approach reveals structure-function relationships.
Knock-in
Knock-in of reporter tags or humanized alleles enables tracking of guanylate cyclase activity. Tagged knock-in of cGMP biosensors allows real-time imaging. Knock-in of human GUCY2C into mouse models facilitates testing of targeted therapies. These models are valuable for translational research.
Overexpression
Overexpression of guanylate cyclases or their positive regulators can amplify cGMP signaling. Overexpression of CARD11 enhances T cell activation. Overexpression of NPR1 increases cGMP production in response to natriuretic peptides. Such models help identify gain-of-function effects and drug targets.
How EDITGENE Supports positive regulation of guanylate cyclase activity Research
Researchers studying positive regulation of guanylate cyclase activity-related genes often need to determine whether a candidate gene is causally involved in cGMP signaling or merely correlated with it. EDITGENE provides the CRISPR tools and cell models to establish causality with precision.
Contact EDITGENE today to design your custom CRISPR model for positive regulation of guanylate cyclase activity research.
Frequently Asked Questions About positive regulation of guanylate cyclase activity
What is GO:0031284?
GO:0031284 is the Gene Ontology term for positive regulation of guanylate cyclase activity, defined as any process that activates or increases the frequency, rate or extent of guanylate cyclase activity.
What genes are involved in positive regulation of guanylate cyclase activity?
Key genes include GUCY1A1, GUCY1B1, NPR1, NPR2, CARD11, AKR1A, and NOS3, among others.
How is guanylate cyclase activity positively regulated?
It can be positively regulated by ligand binding, allosteric modulators, phosphorylation, and protein-protein interactions.
What diseases are associated with dysregulated guanylate cyclase activity?
Cardiovascular disease, cancer, neurobehavioral disorders, and metabolic diseases are linked to altered guanylate cyclase regulation.
What is the role of cGMP in positive regulation of guanylate cyclase activity?
cGMP is the product of guanylate cyclase activity and serves as a second messenger that mediates downstream effects.
How can CRISPR be used to study positive regulation of guanylate cyclase activity?
CRISPR knockout, point mutation, knock-in, and overexpression models allow causal testing of genes in this pathway.
What are the research methods for studying guanylate cyclase activity?
Common methods include radioenzymatic assays, FRET biosensors, RNA-seq, and CRISPR screens.
Which cell models are best for studying guanylate cyclase regulation?
Endothelial cells, cardiomyocytes, neurons, and immune cells are commonly used, depending on the pathway of interest.
What is the difference between soluble and particulate guanylate cyclase?
Soluble guanylate cyclase is activated by nitric oxide, while particulate guanylate cyclase is activated by natriuretic peptides.
How does EDITGENE support research on GO:0031284?
EDITGENE provides CRISPR cell models, library screening, and bioinformatics to study positive regulation of guanylate cyclase activity.
Conclusion
Positive regulation of guanylate cyclase activity (GO:0031284) is a fundamental biological process that controls cGMP synthesis and downstream signaling in health and disease. Understanding its mechanisms, key genes, and regulatory inputs is essential for developing therapies targeting cardiovascular, oncological, and neurobehavioral disorders. CRISPR-based models and advanced screening technologies offer powerful tools to dissect this pathway with precision. EDITGENE stands ready to support researchers in generating custom cell models and bioinformatics solutions for guanylate cyclase research.
References
- 1. Hu Y et al.. 2025. CARD11 signaling regulates CD8(+) T cell tumoricidal function.. Nat Immunol 26(7):1113-1126 PMID: 40533509
- 2. Iino K et al.. 2026. Pentosidine accumulation induced by Akr1a deficiency drives aggression and hyperactivity.. Neurosci Lett 877:138557 PMID: 41730470
- 3. van Duijvenboden K et al.. 2019. Conserved NPPB+ Border Zone Switches From MEF2- to AP-1-Driven Gene Program.. Circulation 140(10):864-879 PMID: 31259610
- 4. Jin L et al.. 2023. Endothelial-dependent relaxation of α-pinene and two metabolites, myrtenol and verbenol, in isolated murine blood vessels.. Am J Physiol Heart Circ Physiol 325(6):H1446-H1460 PMID: 37889254
- 5. Earp HS. 1980. The role of insulin, glucagon, and cAMP in the regulation of hepatocyte guanylate cyclase activity.. J Biol Chem 255(19):8979-82 PMID: 6106019
- 6. Sangaralingham SJ et al.. 2021. Discovery of small molecule guanylyl cyclase A receptor positive allosteric modulators.. Proc Natl Acad Sci U S A 118(52) PMID: 34930837
- 7. Rahman H et al.. 2020. Characterization of tomato protein kinases embedding guanylate cyclase catalytic center motif.. Sci Rep 10(1):4078 PMID: 32139792
- 8. Pilz RB et al.. 2003. Regulation of gene expression by cyclic GMP.. Circ Res 93(11):1034-46 PMID: 14645134
